Novartis Inks Second Off-Label Settlement With DoJ, Paying $72.5 Million Over TOBI Marketing
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis still faces government investigations over its marketing of five other drugs; FDA issues a warning letter over its promotion of Gleevec on two company-sponsored websites.
You may also be interested in...
Health Care Fraud Tipsters May Get Bigger Reward; Novartis Kickback Complaint Prompts CIA Review
HHS proposes to increase the potential reward for information leading to recovery of Medicare funds from $1,000 to $9.9 million; OIG is reviewing Novartis corporate integrity agreement compliance after government alleges company paid Myfortic kickbacks to pharmacies.
The Era Of Billion Dollar Pharma Settlements
Abbott Laboratories is the third pharmaceutical company to reach a settlement with the Department of Justice in excess of $1 billion. A look at the deals struck since Eli Lilly began the billion dollar club in 2009 shows the activities the government is investigating and the level of liability that companies face.
Novartis Advertising Cited By FDA For Fifth Time In Less Than A Year
CBER's Advertising and Promotional Labeling Branch says that Novartis improperly expanded the age range for its Fluvirin influenza vaccine.